Merck and AstraZeneca &amp.

Merck and AstraZeneca & Co., Inc. Type Pioneering Collaboration Merck and AstraZeneca & Co ., Inc. Will collaboration to analyze a novel mixture anticancer regimen made up of two investigational substances, MK-2206 from Merck and AZD6244 from AstraZeneca. Preclinical proof indicates that mixed administration of the compounds could improve their anticancer properties. This is actually the first-time that two huge pharmaceutical companies established a collaboration to judge the prospect of combining applicant molecules at this early stage of advancement.